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Abstract
OBJECTIVES: Typical carcinoids (TCs) are uncommon, slow-growing neoplasms, usually with high 5-year survival rates. As these are rare
tumours, their management is still based on small clinical observations and no international guidelines exist. Based on the European Society
of Thoracic Surgeon Neuroendocrine Tumours Working Group (NET-WG) Database, we evaluated factors that may influence TCs mortality.
METHODS: Using the NET-WG database, an analysis on TC survival was performed. Overall survival (OS) was calculated starting from the
date of intervention. Predictors of OS were investigated using the Cox model with shared frailty (accounting for the within-centre correl-
ation). Candidate predictors were: gender, age, smoking habit, tumour location, previous malignancy, Eastern Cooperative Oncology
Group (ECOG) performance status (PS), pT, pN, TNM stage and tumour vascular invasion. The final model included predictors with
P ≤ 0.15 after a backward selection. Missing data in the evaluated predictors were multiple-imputed and combined estimates were
obtained from five imputed data sets.
RESULTS: For 58 of 1167 TC patients vital status was unavailable and analyses were therefore performed on 1109 patients from 17 institutions
worldwide. During a median follow-up of 50 months, 87 patients died, with a 5-year OS rate of 93.7% (95% confidence interval: 91.7–95.3).
Backward selection resulted in a prediction model for mortality containing age, gender, previous malignancies, peripheral tumour, TNM stage
and ECOG PS. The final model showed a good discrimination ability with a C-statistic equal to 0.836 (bootstrap optimism-corrected 0.806).
†Presented at the 22nd European Conference on General Thoracic Surgery
Copenhagen, Denmark, 15th–18th June 2014.
© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
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CONCLUSIONS: We presented and validated a promising prognostic model for TC survival, showing good calibration and discrimination
ability. Further analyses are needed and could be focused on an external validation of this model.
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INTRODUCTION
Neuroendocrine tumours (NETs) of the lung are a separate clinical
subgroup of primary lung tumours, which share particular mor-
phological, ultrastructural, immunohistochemical and molecular
characteristics. According to the 2004 World Health Organization
(WHO) tumours classification [1] they are categorized into four
major groups, ranging from the low-grade typical carcinoids (TCs),
to highly aggressive, poorly differentiated tumours [large-cell neu-
roendocrine carcinoma (LCNC) and small-cell lung cancer (SCLC)].
Amid them, an intermediate-grade neoplasm [atypical carcinoid
(AC)] is characterized by a greater aggressive biological behaviour
compared with TC, a poorer 5-year survival and a higher tendency
to lymph-nodal involvement at presentation. A recent study [2],
according to the surveillance, epidemiology and end results
(SEER) data, demonstrated a significant increase in the reported
overall NET incidence in the last decades. Actually, the estimated
NET incidence is 5.25 cases/100 000 persons and their predictable
prevalence in the USA is 35 cases/100 000 [2], making these neo-
plasms significantly more common than oesophageal, gastric,
pancreatic and hepatobiliary cancers in the USA [3].
Bronchial carcinoids (BCs) actually represent 1.2% of all primary
lung tumours [3] and can be histologically divided into: TCs, with
highly organized carcinoid architecture and less than two mitoses/
10 high-power fields (HPFs), and ACs, with greater mitotic activity
(2–10/10 HPF) and focal or discrete necrosis [1]. Their incidence
has also rapidly increased in the last three decades [4], partly ex-
plained with the improvement of diagnostic procedures, and with
the lung cancer screening programme development and diffusion.
Although BCs generally have a better prognosis than adenocarcin-
omas, they become incurable once they advance to an unresect-
able metastatic disease. New therapeutic approaches (systemic
chemotherapy, biological agent, targeted therapy or peptide recep-
tor radiotherapy) have been proposed, with conflicting results, and
the lack of randomized clinical studies is mainly due to the rarity of
the disease.
In 2012, the European Society of Thoracic Surgeons (ESTSs)
launched a new scientific project, the NETs of the Lung Working
Group (WG), with the aim of gathering a group of experts world-
wide, developing knowledge on such rare neoplasms and dissem-
inating it within the scientific community. A dedicated database
was designed, approved by the ESTS NETs-WG Steering Committee
and used to start a retrospective patient database.
Up to 31 January 2014, a series of 2059 NETs patients have
been collected among 17 Thoracic Surgery Institutions worldwide
(see Supplementary material, Table S1). Using this retrospective
database, we intentionally focused on the outcome of TCs. The
aim of this study was to develop an additive scoring system and to
assess its association with survival in patients who underwent
curative resection for TC.
PATIENTS ANDMETHODS
This is a retrospective, multicentre cohort study of patients oper-
ated for TCs between 1994 and 2012 at 17 high-volume European
Thoracic Surgery Institutions. Data were obtained from the ESTS
NETs-WG retrospective database.
Demographic and clinico-pathological characteristics were col-
lected: age, gender, smoking habit, previous malignancies, tumour
location, Eastern Cooperative Oncology Group (ECOG) perform-
ance status (PS), type of intervention, TNM stage, tumour vascular
invasion, induction/adjuvant therapy.
We adopted the ‘tumour location’ definition previously re-
ported by Detterbeck [5]: all those tumours directly visualized at
bronchoscopy or in association with lung atelectasis and/or ob-
structive pneumonia were classified as ‘central’, whereas ‘periph-
eral’ lesions where those not observed at bronchoscopy.
The type of surgical resection was recorded and classified as ‘ana-
tomical’ (segmentectomy, lobectomy, bilobectomy or pneumonec-
tomy) and ‘non-anatomical’ (wedge resection). Bronchoplastic
procedures (i.e. sleeve lobectomy) were included within the lob-
ectomy group. Lymph-nodal dissection data were also collected.
All the histological samples were reviewed by local pathologists
and the definitive TC histological diagnosis was done according
to the 2004 WHO lung tumours classification [6] and to the
Travis’ histological guidelines for lung NETs diagnosis [7]. Tumours
staging was classified according to the seventh edition of the TNM
staging system for malignant lung tumours [8].
Statistical analysis
For patient characteristics, continuous data are presented as median
(interquartile (IQR)] and categorical data as frequency with
percentage.
Overall survival (OS) was the primary outcome. OS was calcu-
lated from the date of surgery to the date of death from any cause
or the date of the last follow-up. OS curves were computed using
the Kaplan–Meier method. Predictors of OS were investigated
using the Cox model with shared frailty (accounting for the within-
centre correlation). Candidate predictors were: age (as continu-
ous), gender, smoking habit (never or former/current smoking),
previous malignancy, tumour location (central or peripheral),
ECOG PS (0, 1-2, ≥3), pT, pN, TNM stage and tumour vascular in-
vasion. Missing data in the evaluated baseline predictors were
multiple-imputed and combined estimates were obtained from
five imputed data sets. The imputation of missing data was not
performed for the outcome variables. A sensitivity analysis based
on complete data patients was also performed.
To prevent overfitting, the final model included predictors
with P ≤ 0.15 after a backward selection. C-statistic was used to de-
termine the discrimination ability of the proposed model. The
predicted 5-year survival probabilities were compared with the
observed frequencies using a calibration plot to assess the calibra-
tion of the model. It was internally validated in order to evaluate
the optimism of the model. Two hundred bootstrap samples were
drawn from the original data set with replacement and within
each bootstrap sample the entire modelling process described
above, including the backward stepwise selection of predictors,
was repeated. The optimism-corrected C-statistic was estimated
according to bootstrap process results. To simplify the calculation
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of the survival probabilities for single patients, the Cox model has
been displayed through an easy-to-use nomogram.
For the purpose of designing an additive score, numerical vari-
ables were computed according to the proportion between each
predictor’s coefficient and the lowest one. To simplify the score
calculation, the selected final model was re-estimated including
age as categorical (<55, 55–64, 65–74, ≥75 years). Patients were
then grouped in classes of risk according to their total score.
Statistical analyses were performed with Stata (version 12.1) and
R (version 3.0.2).
RESULTS
Figure 1 shows the study flow of the patient population.
Between 1994 and 2012, a series of 2059 patients operated for
NETs were evaluated; of these, 1167 (57%) cases were identified as
TC. Analyses were performed on data of 1109 patients with com-
plete information for OS analysis. Clinical and demographic char-
acteristics of analysed population are summarized in Table 1.
Patients affected by TC were more frequently females (712,
64%) and never-smokers (601, 54%). One-hundred and ninety-
one (17%) experienced a previous malignancy. Median age at
intervention was 59 years (IQR: 46–68); centrally located neo-
plasms were 457 (61%) on the 754 with available information.
Surgical procedures are summarized in Table 2.
During a median follow-up of 50 months, 87 patients died; the
5-year OS was 93.7% [95% confidence interval (CI): 91.7–95.3] (Fig. 2).
The final Cox model (Table 3), deriving from the backward se-
lection, showed that mortality was associated with: increased age
[per 1 year increase, hazard ratio (HR): 1.07; 95% CI: 1.05–1.09,
P < 0.001], male gender (HR: 2.18; 95% CI: 1.39–3.43, P = 0.001),
the presence of previous malignancies (HR: 1.88; 95% CI: 1.16–
3.05, P = 0.010), pTNM stage (II vs I: HR: 2.19; 95% CI: 1.13–4.21,
P = 0.019; III vs I: HR: 3.77; 95% CI: 1.56–9.13, P = 0.003) and ECOG
PS (1-2 vs 0: HR: 2.04; 95% CI: 1.1–3.76, P = 0.023; ≥3 vs 0: HR:
3.49; 95% CI: 0.32–38.7, P = 0.300). The final model showed a good
discrimination ability with a C-statistic equal to 0.836 (optimism-
corrected 0.806). Using an approach based on a standard Cox
model without taking into account the shared frailty, the same
predictors were selected by obtaining very similar effect estimates.
The sensitivity analysis based on patients with complete data
showed a reduction of the effect on risk of death for previous ma-
lignancy (HR: 1.41 vs 1.88) and intermediate pTNM (HR: 1.17 vs
2.19), whereas we observed an increase of effect on risk of death
for male gender (5.01 vs 2.18) and high ECOG PS (8.60 vs 3.49).
However, the subgroup of patients with incomplete data on all
Figure 1: Study flow chart.
Table 1: Patient characteristics (n = 1109)
n Missing (%)
Age 1109 0
Median (IQR) 59 (46;68)
Mean (range) 56.7 (11–90)
Males 1109 397 (36%) 0
Smokers (current/former) 1109 508 (46%) 0
Previous malignancy 1109 191 (17%) 0
Central tumour 754 457 (61%) 355 (32%)
ECOG PS 902 207 (19%)
0 785 (87%)
1-2 113 (13%)
≥3 4 (0%)
pTNM 1109 0
I 955 (86%)
II 109 (10%)
III 45 (4%)
Pt 1078 31 (3%)
t1 828 (77%)
t2 214 (20%)
t3 30 (3%)
t4 6 (1%)
pN 1109 0
N0 975 (88%)
N1 65 (6%)
N2 29 (3%)
Nx 40 (4%)
cN 869 240 (22%)
n0 806 (93%)
n1 40 (5%)
n2 23 (3%)
Adjuvant therapy 908 17 (25) 201 (18%)
Induction therapy 908 6 (<1%) 201 (18%)
Vascular invasion 880 79 (9%) 229 (21%)
Missing variablesa 1109
None 380 (34%)
Only 1 435 (39%)
Only 2 257 (23%)
3 or more 37 (3%)
aConsidering all the variables mentioned in the table.
Table 2: Surgical interventions (n = 1109)
Type of intervention n %
Wedge resection 130 11.8
Segmentectomy 81 7.3
Lobectomy 706 63.7
Sleeve resection 77 6.9
Bilobectomy 82 7.4
Pneumonectomy 29 2.6
Extended resection 1 0.1
Missing data 3 0.2
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the above selected covariates showed a significantly lower prob-
ability of survival compared with patients with complete data
(HR: 1.74, 95% CI: 1.11–2.71, P = 0.015). Figure 3 shows the calibra-
tion of the model, with a good agreement between observed and
predicted 5-year survival, over the whole range of probabilities.
Finally, Fig. 4 shows the designed Nomogram, which is able to
predict 5-year survival of TCs.
Table 3 also summarizes results of Cox model according to age
as categorical variable (<55 years; 55–64 years; 65–74 years and
>75 years), in order to simplify the calculation of additive score.
This simplification results in a little reduction of discrimination
ability of the model with a C-statistic equal to 0.822 (optimism-
corrected 0.795).
Based on their regression coefficients of similar magnitude, a
weighted score was created, assigning points according to the
rounded to integer proportion with the lower one (peripherally
located tumour equal to 1 point).
Based on the additive score results, patients were grouped into
four risk classes: A (≤1 point, 378 patients), B (2–3 points, 459
patients), C (4–5 points, 234 patients) and D (≥6 points, 38
patients). Figure 5 shows the overall survival (OS) Kaplan–Meier
estimates by additive risk score classes (P < 0.001). The 5-year sur-
vival rates for the four classes were: A: 99.7%, B: 96.3%, C: 84.2%
and D: 53.9%.
DISCUSSION
The incidence of BCs has rapidly increased in the last three
decades, partly due to the improvement in diagnostic procedures
as well as in their recognition through simplified histopathological
procedures [4]. A key role has also been played by the dramatic
development and diffusion of lung cancer screening programmes,
which increased the likelihood of detecting small peripheral lung
nodules in high-risk subjects.
On the other hand, lung NETs clinical management has recently
become more multidisciplinary, involving not only surgeons, but
also medical and radiation oncologists, pathologists, interventional
pulmonologists. The recent development of new, effective che-
motherapeutic molecules, along with biological agents, has re-
sulted in a more effective treatment of advanced tumours, which
were previously regarded as untreatable.
The interest in lung NETs and the recognition that a global
effort is needed in their management has led to the development
of multicentre experiences [9], retrospectively collecting a cohort
of patients as large as possible, to establish outcome and potential
prognostic factors for such rare neoplasms. ESTS has taken steps
in this direction, creating an international working group of
experienced physicians in lung NETs; within the first 2 years
Figure 2: Overall survival (OS) Kaplan–Meier estimates. Marks represent censor-
ing times.
Table 3: Predictors of overall survival using Cox proportional hazard models (n = 1109)
Age as continuous Age as categorical
HR (95% CI) P-value HR (95% CI) P-value Coefficient Score
Age as continuous, (per 1 year increase) 1.07 (1.05–1.09) <0.001 – – – –
Age as categorical
<55 (Ref.) – – 1 – – 0
55–64 – – 2.54 (1.15–5.59) 0.021 0.931 1
65–74 – – 4.18 (1.99–8.79) <0.001 1.431 2
≥75 – – 10.36 (4.66–23.03) <0.001 2.338 3
Male 2.18 (1.39–3.43) 0.001 2.2 (1.4–3.47) 0.001 0.790 1
Previous malignancy 1.88 (1.16–3.05) 0.010 1.95 (1.2–3.16) 0.007 0.669 1
Peripheral tumour 1.89 (0.78–4.59) 0.142 2.05 (0.88–4.81) 0.091 0.719 1
pTNM
I (Ref.) 1 – 1 – – 0
II 2.19 (1.13–4.21) 0.019 2.1 (1.09–4.04) 0.026 0.743 1
III 3.77 (1.56–9.13) 0.003 3.74 (1.55–9.02) 0.003 1.320 2
ECOG PS
0 1 – 1 – – 0
1–2 2.04 (1.1–3.76) 0.023 2.05 (1.11–3.8) 0.023 0.718 1
≥3 3.49 (0.32–38.7) 0.300 4.16 (0.34–50.87) 0.255 1.425 2
C-statistics
Original sample 0.836 0.822
Optimism-corrected 0.806 0.795
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activity, more than 2000 patients have been retrospectively col-
lected from 17 high-volume international Thoracic Surgery
Centres through an ad hoc designed database. This database has
been use for the purposes of this study.
Main findings
Several papers have been recently published on single-centre
experiences on lung NETs [10–13], but to the best of our knowl-
edge, this is the first report focussing on identifying factors asso-
ciated with survival and incorporating them into a single additive
score.
We found that mortality was associated with increased age,
male gender, the presence of previous malignancies, peripheral
tumours, TNM stage and ECOG PS. These variables were used to
construct an additive score, enabling one to identify four risk
classes, according to the specific weight of each independent pre-
dictor. In this way, Class A patients experienced a 5-year survival
of 99.7%, Class B, 96.3%, Class C, 84.2% and Class D, 53.9%.
Evidence
There are several reports on the association of age and prognosis
in patients affected by non-small-cell lung cancers (NSCLCs): in
general, most of them indicate that surgery in early-stage NSCLC
is effective in elderly patients, and produces similar survival results
than in younger ones [14]. On the contrary, a recent SEER analysis
found that elderly patients presented with a worse survival, which
was independent of sex, stage or histology [15].
Our results confirm that age (both as continuous and as cat-
egorical covariates) as well as male gender have a negative impact
on patients’ survival, as recently reported [16, 18]. The correlation
between lung neoplasm and male gender may be partly explained
by the smoking habits of the patients.
This is the first time in which a previous malignancy is reported
to be a negative predictive variable in BCs. A recent SEER analysis
[19] described 329 (13.9%) out of 2374 carcinoid patients who
had a primary cancer diagnosed prior to the lung neoplasm, and
163 (7.4%) who presented with another cancer at the same time
of the carcinoid diagnosis; however, no data are reported about
both outcome of these patients and the possble prognostic role
of second cancers. In particular, an increased risk to develop
prostate and breast cancer was observed. The authors postulated
that the growth of BCs may be partly the result of a genetic pre-
disposition or environmental factors, particularly with regard to
hormonally-related neoplasms. The role of genetics and sex hor-
mones in lung carcinoid development, as well as the identifica-
tion of other risk factors, should be further explored.
A possible explanation for the negative prognostic value of a
peripheral tumour location may be the absence of symptoms,
compared with the central site. When the carcinoid grows in a
main bronchus, in fact, cough, dyspnoea, recurrent pneumonia
and haemoptysis usually occur, and an earlier tumour diagnosis is
often possible [5, 20]. A prolonged treatment for an infection or
asthma is sometimes possible, and this may predate tumour
diagnosis, especially in young patients. In the absence of clinical
symptoms, peripheral lesions remain undetected for a long time,
or are occasionally discovered on chest X-rays performed for
other reasons.
In 2008, the International Association for the Study of Lung
Cancer (IASLC), joining SEER and IASLC databases, proposed to
extend the seventh TNM classification to also include broncho-
pulmonary carcinoids [21]. Since then other publications have
followed this suggestion [13, 17]; our data strongly confirm that
the new TNM stage classification is effective in predicting prog-
nosis in BCs.
Figure 3: Calibration plot describing the relationship between the predicted
versus observed 5-year survival. Predictions were based on the model including
age as a continuous variable).
Figure 4: Nomogram derived from the Cox model.
Figure 5: Overall survival Kaplan–Meier estimates by additive risk score. Data
points represent censoring times.
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There is a large body of evidence concerning the prognostic
role of the patient’s PS in primary lung cancers. PS can be
assessed using several tools: we adopted the ECOG scale [22],
which demonstrated to be an independent variable influencing
survival.
Study limitations
Possible study limitations are as follows:
(i) A potential intrinsic limitation is its retrospective and multi-
centric nature. Nevertheless, the use of the ESTS NETs lung
database allowed us to collect a large cohort of patients from
high-volume International Thoracic Surgery Institutions. Their
well-known clinical expertise in the field of NETs as well as
the use of shared frailty survival models add a statistical ro-
bustness to our results.
(ii) A centralized histological review process was not available;
however, all the histological specimens were reviewed by
local pathologists and the definitive TC diagnosis was done
according to uniform histological guidelines (the 2004 WHO
Lung Tumors Classification and Travis’ histological advice for
NETs diagnosis).
(iii) The lack of a ‘really’ independent data set for model valid-
ation represents a weakness of this work; despite the model
being internally validated using bootstrapping techniques, an
external validation will be needed to evaluate the perform-
ance in other populations before implementing the predic-
tion model in clinical practice.
Clinical inferences and conclusions
We presented a promising prognostic model for TC survival,
showing a good calibration and discrimination ability. Its discrim-
inative ability can be used to refine prognostic stratification in
patients with TC who have undergone lung resection. Patients
with a high score can be easily identified and counselled for a
stricter follow-up. Future clinical investigations can be proposed
to explore the feasibility of adjuvant treatments in patients with a
high score, as well as their possible enrolment in prospective clin-
ical trials to test the efficacy of new chemotherapeutic molecules
in treating such rare neoplasms.
Further analyses could also focused on an external validation of
this model, to facilitate its possible clinical application.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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APPENDIX. CONFERENCE DISCUSSION
Dr P.-E. Falcoz (Strasbourg, France): You clearly show in your work the interest
of the thoracic surgical community in lung neuroendocrine tumours, which
recognizes that a global effort is needed in their management. In fact, ESTS has
taken steps in this direction, creating a worldwide Working Group of experi-
enced physicians in lung neuroendocrine tumours. In the first two years of ac-
tivity of this Working Group, through an ad hoc designed database, more than
2,000 patients have been retrospectively collected in 17 high volume inter-
national centres. This database has been used for the purpose of your study.
Dr Filosso, your study is the first report focused on identifying factors asso-
ciated with survival and incorporating them into a single additive score. You
found that mortality was associated with increased age, male gender, the pres-
ence of previous malignancy, peripheral tumours, TNM stages, and ECOG PS.
You used these variables to construct your additive score, making it possible to
identify four risk classes. Few studies in the past 10 years have sought to address
this very interesting but seldom debated question of the prognosis of typical
bronchial carcinoid tumours, and, for the most part, as you acknowledge, have
been single institutions and retrospective cohorts. I am sure that your article
will help to clarify some of these controversies, and its main findings may well
have a relevant impact on the follow-up of these patients. I have three ques-
tions for you.
First, you postulate in your discussion that bronchial carcinoid growth may
be partially the result of a genetic predisposition. Exploring the role of genetics
and sex hormones in lung carcinoid could be very innovative indeed. Do you
have any key data and clues to go one step further in this discussion?
Dr Filosso: Looking at your first question, very few data are available in the lit-
erature concerning the role of both sex hormones and genetic abnormalities in
tumour growth and outcome of these rare tumours. If you consider the Lung
Cancer Genomic Program, a loss of heterozygosity has been observed, espe-
cially in high grade tumours (large cell neuroendocrine carcinoma as well as
small cell lung cancer), but it was not observed in the bronchial carcinoid. This
means that even if they belong to the same biological family, those two types
of tumours are different in terms of genetics. Loss of heterozygosity was
detected especially in RP locus, in 3P and in p53; p53 was observed in high
grade tumours, but was absent in typical carcinoids, and present in 23% of atyp-
ical carcinoids, showing the genetic differences between typical and atypical
carcinoids. Currently we have no data concerning the genetic abnormalities in
our patients.
During the business meeting of the ESTS Neuroendocrine Tumours Working
Group yesterday we discussed the implementation of data and probably genet-
ics will be included in the future.
Dr Falcoz: Second question. As you acknowledge in your manuscript, an ex-
ternal validation of your prognostic model is in fact mandatory. How do you
plan to perform this external validation? By means of a pure bootstrap artificial
statistical technique or by link with an historical cohort? Could you please give
us more information and your point of view on this particular point?
Dr Filosso: I think that there are two possibilities to answer your question.
First, keeping in mind that this is probably the largest series ever collected, we
could improve the numbers of our patients and we could perform further boot-
strapping and statistical analysis to validate the model. But we also have
another possibility. We could propose this model to other institutions which
have not yet uploaded their data to our database, and if it fits, we could achieve
an external validation of the model.
Dr Falcoz: I think that is a nice idea. Finally, what will your next step be in
your research work? Will you consider refining your score when more patients
are included prospectively?
Dr Filosso: Thank you very much for this question because it allows me to
remind everybody that there is a next step with this database: a prospective
database has recently been elaborated. We used the retrospective one and
we merged it with the ESTS-endorsed database, making possible a sort of
new NETs registry, which is actually available for a demo at the Dendrite
booth during the Congress. Finally, as soon as the definitive version is elabo-
rated, each of you could include your patients in this database. I hope that in
two or three years we will dramatically improve the numbers of neuroendo-
crine tumours in the database and we will be able to assess new prognostic
factors, especially for the so-called grey zone (atypical carcinoid), which was
the object of another paper from this group at the Birmingham meeting
last year.
Dr Falcoz: You are to be congratulated for your in-depth work, and from the
point of medical care, your results will certainly prove to be very beneficial to
the thoracic surgical community.
Mr P. Goldstraw (London, UK): Carcinoid tumours, and in particular typical
carcinoid tumours, are indolent and even relapsed patients can live for
many, many years with recurrent disease. If we are to understand how to use
your nomogram, then we need disease-specific survival. Have you got
any data on this? Are you collecting the causes of death and disease-specific
survival?
Dr Filosso: We had 87 patients who died in the period of the study, and the
majority of them died from tumour-related causes. Currently we have no data
concerning disease-specific survival, but I am confident we will be able to
improve our data regarding this issue in the future.
Mr D. Waller (Leicester, UK): I have two young female, non-smoking, good
performance patients in whom I have diagnosed typical carcinoid tumours by
endobronchial laser ablation. In view of your knowledge of the subject and
your prognostic indicators, do I now need to perform any further surgery on
these good prognosis patients?
Dr Filosso: I think that you have to operate.
Mr Waller: Will I get any data to support that decision in the future based on
your 1,000-patient database?
Dr Filosso: I don’t have the exact number of bronchial resected tumours
(probably 25-–28 cases), but all the patients went to surgery after the broncho-
scopic resection.
Dr J. Schirren (Wiesbaden, Germany): I think it is a good idea to find scores. It
is interesting that in your series you have only 6% N1 disease and 3% N2
disease. This is very low if you compare this with the literature. Now, the ques-
tion is, you have 17 centres: how extensive was lymph node dissection?
Dr Filosso: The majority performed lymph node dissection, not lymph node
sampling. Therefore data concerning N1 and N2 are real in terms of removal of
all lymph nodes, even if this is a retrospective database. We now know that we
are moving to systematic lymph node resection, and I can assure you that the
majority of centres did perform this procedure.
Dr Schirren: How many nodes did you resect?
Dr Filosso: I am not able to answer your question at this time, but will include
it in the paper.
Dr E. Lim (London, UK): I have one comment and one question. My
comment is that bootstrap analysis is a different way of getting a confidence
interval. It won’t help you revalidate or redesign your model. So that is not the
appropriate use of bootstrapping. Looking at the overall predictors, I noticed
that TNM is probably the strongest influencing predictor, with T4 and stage 4
status having odds ratios of 51 and 24 respectively. So my question is, how
much better is this prognostic model compared to the use of TNM alone?
Dr Filosso: This is a very good question. I think that only by improving the
number of the patients included in this model could we have an answer to your
question. I think that TNM should be the best variable in the model.
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